Studies how the body handles SHR-3167 in adults with type 2 diabetes
Tests how SHR-3167 moves through the body in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes
Key facts
- Where
- Chengdu, ChinaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 59 years old?
Source: NCT07032688, who can take part
Where in China
- West China Hospital of Sichuan UniversityChengdu, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jiangsu HengRui Medicine Co., Ltd.
- Trial code
- NCT07032688
- Record updated
- 17 April 2026
- Original description
The objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of SHR-3167 at steady state in subjects with type 2 diabetes.Read full original descriptionShow less
A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 Injection at Steady State in Subjects With Type 2 Diabetes
The objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of SHR-3167 at steady state in subjects with type 2 diabetes.
Inclusion: Informed consent obtained before any trial-related activities; Age 18~59 years at screening (including cut-off values at both ends); Confirmed diagnosis of type 2 diabetes mellitus ≥ 6 months before screening; Female subjects of childbearing potential and their partners are male subjects of childbearing potential, who have no fertility plan and agree to take high-efficiency contraceptive measures within 3 months after signing the informed consent form and have no plans to donate eggs/sperm; Female subjects of childbearing potential have a negative pregnancy test during the screening period and are not lactating.
Exclusion: Known or suspected allergy to investigational drug products or related products; or a history of multiple and/or severe allergies to drugs or foods; Serious cardiovascular and cerebrovascular diseases within 6 months prior to screening; Participation in any clinical trial of an approved or unapproved investigational drug/medical device within 90 days prior to screening; Positive test for hepatitis B surface antigen (HBsAg), HIV antibody, treponema pallidum specific antibody, or hepatitis C virus antibody; or the investigator judges that the subject is in the incubation or active phase of the above infection; Malignancy or history of malignancy within 5 years prior to screening; Any other condition judged by the investigator to be likely to affect the subject's safety or interfere with the evaluation of trial results; Poor blood pressure control at screening.